Company · CIK 0001623526 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
Stoke Therapeutics, Inc. · STOK
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 SForm 4 → | Sep 3, 4:17 pm EDT | Barry TichoCHIEF MEDICAL OFFICER | 5,545 | $30.67 | $170,061 | 20,110 | −21.6% | 10b5-1 |
| Aug 18, 2026 SForm 4 → | Aug 18, 8:29 pm EDT | Barry TichoCHIEF MEDICAL OFFICER | 4,767 | $32.03 | $152,690 | 25,655 | −15.7% | |
| Aug 18, 2026 SForm 4 → | Aug 18, 8:28 pm EDT | Edward M. Kaye M.D.Director | 12,567 | $32.03 | $402,528 | 124,557 | −9.16% | |
| Aug 18, 2026 SForm 4 → | Aug 18, 8:27 pm EDT | Jonathan AllanGENERAL COUNSEL & CORP SEC | 2,861 | $32.03 | $91,639 | 21,225 | −11.9% | |
| Aug 14, 2026 MForm 4 → | Aug 18, 8:29 pm EDT | Barry TichoCHIEF MEDICAL OFFICER | 10,000 | — | — | 30,422 | — | |
| Aug 14, 2026 MForm 4 → | Aug 18, 8:28 pm EDT | Edward M. Kaye M.D.Director | 26,250 | — | — | 137,124 | — | |
| Aug 14, 2026 MForm 4 → | Aug 18, 8:27 pm EDT | Jonathan AllanGENERAL COUNSEL & CORP SEC | 6,000 | — | — | 24,086 | — | |
| Aug 3, 2026 SForm 4 → | Aug 5, 4:17 pm EDT | Barry TichoCHIEF MEDICAL OFFICER | 7,176 | $29.04 | $208,385 | 20,422 | −26.0% | 10b5-1 |
| Jul 1, 2026 SForm 4 → | Jul 6, 4:10 pm EDT | Barry TichoCHIEF MEDICAL OFFICER | 7,228 | $32.66 | $236,068 | 27,598 | −20.8% | 10b5-1 |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 23, 2026 AForm 4 → | Sep 25, 4:12 pm EDT | Alexander CumboDirector | 39,674 | — | — | 39,674 | — | |
| Aug 14, 2026 MForm 4 → | Aug 18, 8:29 pm EDT | Barry TichoCHIEF MEDICAL OFFICER | 10,000 | — | — | 0 | — | |
| Aug 14, 2026 MForm 4 → | Aug 18, 8:28 pm EDT | Edward M. Kaye M.D.Director | 26,250 | — | — | 0 | — | |
| Aug 14, 2026 MForm 4 → | Aug 18, 8:27 pm EDT | Jonathan AllanGENERAL COUNSEL & CORP SEC | 6,000 | — | — | 0 | — | |
| Jul 16, 2026 GForm 4 → | Jul 17, 4:37 pm EDT | Seth Loring HarrisonDirector | 303,190 | — | — | 17,786 | — | |
| Jul 15, 2026 AForm 4 → | Jul 17, 4:35 pm EDT | Thomas McCauleyChief Scientific Officer | 225,000 | — | — | 225,000 | — |